Breo Coverage Gaining Ground, GSK’s Witty Assures Investors
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline’s COPD drug Breo Ellipta is facing reimbursement challenges, particularly in terms of Medicare Part D coverage. But CEO Andrew Witty told investors during a year-end sales and earnings call Feb. 5 that coverage is increasing and will continue to grow through 2014.